Stryker Corporation $SYK Shares Sold by Mirabella Financial Services LLP

Mirabella Financial Services LLP reduced its stake in shares of Stryker Corporation (NYSE:SYK) by 66.4% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,567 shares of the medical technology company’s stock after selling 9,035 shares during the period. Mirabella Financial Services LLP’s holdings in Stryker were worth $1,815,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of SYK. Vanguard Group Inc. increased its holdings in shares of Stryker by 1.3% in the 2nd quarter. Vanguard Group Inc. now owns 33,500,571 shares of the medical technology company’s stock valued at $13,253,831,000 after acquiring an additional 440,607 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in Stryker by 9.2% in the first quarter. Price T Rowe Associates Inc. MD now owns 12,131,218 shares of the medical technology company’s stock worth $4,515,847,000 after purchasing an additional 1,021,496 shares during the period. Geode Capital Management LLC increased its stake in Stryker by 1.1% during the second quarter. Geode Capital Management LLC now owns 7,393,611 shares of the medical technology company’s stock valued at $2,910,445,000 after purchasing an additional 79,654 shares during the last quarter. Norges Bank acquired a new stake in shares of Stryker during the second quarter worth $1,882,173,000. Finally, Goldman Sachs Group Inc. lifted its position in shares of Stryker by 13.1% in the 1st quarter. Goldman Sachs Group Inc. now owns 2,252,895 shares of the medical technology company’s stock worth $838,640,000 after buying an additional 261,058 shares during the last quarter. Institutional investors and hedge funds own 77.09% of the company’s stock.

Insider Buying and Selling

In related news, CAO William E. Berry, Jr. sold 1,953 shares of the stock in a transaction that occurred on Friday, November 14th. The shares were sold at an average price of $365.49, for a total transaction of $713,801.97. Following the completion of the sale, the chief accounting officer directly owned 2,833 shares of the company’s stock, valued at $1,035,433.17. This represents a 40.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Ronda E. Stryker sold 276,173 shares of Stryker stock in a transaction that occurred on Thursday, November 6th. The stock was sold at an average price of $353.28, for a total transaction of $97,566,397.44. Following the completion of the transaction, the director owned 2,702,108 shares in the company, valued at approximately $954,600,714.24. This trade represents a 9.27% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 522,118 shares of company stock worth $185,381,932 in the last ninety days. 5.90% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

SYK has been the topic of several research reports. Weiss Ratings reiterated a “hold (c+)” rating on shares of Stryker in a research note on Monday. BTIG Research restated a “buy” rating and set a $410.00 price objective on shares of Stryker in a research report on Friday, November 14th. Needham & Company LLC reaffirmed a “buy” rating and issued a $448.00 target price on shares of Stryker in a research report on Friday, November 14th. UBS Group set a $408.00 price target on shares of Stryker in a report on Monday, October 13th. Finally, Redburn Partners set a $420.00 price objective on shares of Stryker in a report on Thursday, September 18th. Twelve equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat.com, Stryker has a consensus rating of “Moderate Buy” and a consensus price target of $433.78.

Stryker Stock Down 0.6%

Shares of SYK stock opened at $363.92 on Friday. Stryker Corporation has a 1 year low of $329.16 and a 1 year high of $406.19. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.13 and a current ratio of 1.85. The business’s fifty day moving average is $368.44 and its 200-day moving average is $379.67. The stock has a market cap of $139.17 billion, a PE ratio of 47.82, a price-to-earnings-growth ratio of 2.59 and a beta of 0.89.

Stryker (NYSE:SYK) last released its earnings results on Thursday, October 30th. The medical technology company reported $3.19 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.13 by $0.06. Stryker had a return on equity of 24.07% and a net margin of 12.07%.The firm had revenue of $6.06 billion for the quarter, compared to analyst estimates of $6.04 billion. During the same period in the previous year, the company earned $2.87 earnings per share. Stryker’s revenue was up 10.2% compared to the same quarter last year. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. Equities analysts expect that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.